Ramírez-Pérez Oscar, Cruz-Ramón Vania, Chinchilla-López Paulina, Méndez-Sánchez Nahum
Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico.
Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico.
Ann Hepatol. 2017 Nov;16 Suppl 1:S21-S26. doi: 10.5604/01.3001.0010.5672.
The gut microbiota has been considered a cornerstone of maintaining the health status of its human host because it not only facilitates harvesting of nutrients and energy from ingested food, but also produces numerous metabolites that can regulate host metabolism. One such class of metabolites, the bile acids, are synthesized from cholesterol in the liver and further metabolized by the gut microbiota into secondary bile acids. These bioconversions modulate the signaling properties of bile acids through the nuclear farnesoid X receptor and the G protein-coupled membrane receptor 5, which regulate diverse metabolic pathways in the host. In addition, bile acids can regulate gut microbial composition both directly and indirectly by activation of innate immune response genes in the small intestine. Therefore, host metabolism can be affected by both microbial modifications of bile acids, which leads to altered signaling via bile acid receptors, and by alterations in the composition of the microbiota. In this review, we mainly describe the interactions between bile acids and intestinal microbiota and their roles in regulating host metabolism, but we also examine the impact of bile acid composition in the gut on the intestinal microbiome and on host physiology.
肠道微生物群被认为是维持人类宿主健康状态的基石,因为它不仅有助于从摄入的食物中获取营养和能量,还能产生许多可调节宿主新陈代谢的代谢产物。其中一类代谢产物,即胆汁酸,在肝脏中由胆固醇合成,并由肠道微生物群进一步代谢为次级胆汁酸。这些生物转化通过核法尼醇X受体和G蛋白偶联膜受体5调节胆汁酸的信号传导特性,进而调节宿主的多种代谢途径。此外,胆汁酸可通过激活小肠中的固有免疫反应基因,直接或间接地调节肠道微生物组成。因此,宿主代谢可受到胆汁酸的微生物修饰(导致通过胆汁酸受体的信号改变)以及微生物群组成变化的影响。在本综述中,我们主要描述胆汁酸与肠道微生物群之间的相互作用及其在调节宿主代谢中的作用,但我们也研究了肠道中胆汁酸组成对肠道微生物组和宿主生理的影响。
Ann Hepatol. 2017-11
Ann Hepatol. 2017-11
Trends Mol Med. 2015-10-16
Handb Exp Pharmacol. 2019
World J Gastroenterol. 2025-8-7
Mediators Inflamm. 2025-6-18
J Pediatr Gastroenterol Nutr. 2025-5
Front Pharmacol. 2024-10-9